Healthcare stocks were slightly higher today with the NYSE Healthcare Sector Index advancing about 0.2% and shares of healthcare companies in the S&P 500 climbing about 0.3% as a group.
In company news, Aldeyra Therapeutics ( ALDX ) rallied to a new all-time high Thursday after Aegis Capital began coverage of the biotech company working to develop treatments for rare skin and eye diseases with a Buy rating.
Separately, the company today named Stephen Tulipano as its chief financial officer, effective next Monday, June 23.
ALDX shares were up more than 9% at $7.32 each in recent trade, easing somewhat from its session and lifetime high of $8.22 a share earlier today. Through Wednesday's close, the stock has fallen 12.1% since pricing its initial public offering of stock on May 2 at $7.50 a share.
In other sector news,
(+) QGEN, (+0.1%) FDA approves the company's artus CMV RGQ MDx kit to monitor Cytomegalovirus viral load in organ transplant patients. The test runs on QGEN's Rotor-Gene Q MDx PCR platform, which was cleared by the FDA in 2012.
(-) PETX, (-3.7%) Begins enrolling canine patients for a pair of nationwide trials to evaluate its AT-005 monoclonal antibody, which is conditionally licensed by the Department of Agriculture to aid in the treatment of T-cell lymphoma in dogs.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.